Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 6
Submit an article Journal homepage
141
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma

Wisdom Akingbemia Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA;b Drexel University College of Medicine, Philadelphia, PA, USAView further author information
,
Goldie Kurtza Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Nikhil Yegya-Ramana Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USAView further author information
,
John P. Plastarasa Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Stephen J. Schusterc Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USAView further author information
&
Elise A. Chongc Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USACorrespondence[email protected]
View further author information
Pages 860-863 | Received 15 Dec 2023, Accepted 18 Feb 2024, Published online: 07 Mar 2024

References

  • Savage KJ. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):578–586. doi:https://doi.org/10.1182/asheducation-2017.1.578
  • Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139(15):2306–2315. doi:https://doi.org/10.1182/blood.2021014738
  • Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–2554. doi:https://doi.org/10.1056/NEJMoa1708566
  • Pinnix CC, Gunther JR, Dabaja BS, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020;4(13):2871–2883. doi:https://doi.org/10.1182/bloodadvances.2020001837
  • Kasenda B, Loeffler J, Illerhaus G, et al. The role of whole brain radiation in primary CNS lymphoma. Blood. 2016;128(1):32–36. doi:https://doi.org/10.1182/blood-2016-01-650101
  • Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–409. doi:https://doi.org/10.1001/jama.2016.9839
  • Ghilardi G, Chong EA, Svoboda J, et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol. 2022;33(9):916–928. doi:https://doi.org/10.1016/j.annonc.2022.05.521
  • Bennani NN, Maurer MJ, Nastoupil LJ, et al. Experience with axicabtagene ciloleucel (axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium. Blood. 2019;134(Supplement_1):763. doi:https://doi.org/10.1182/blood-2019-129097
  • Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860–866. doi:https://doi.org/10.1182/blood.2019001694
  • Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119–3128. doi:https://doi.org/10.1200/JCO.19.02104
  • Cook MR, Scott Dorris C, Makambi KH, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7(1):32–39. doi:10.1182/bloodadvances.2022008525
  • Ghafouri S, Timmerman J, Larson S, et al. Axicabtagene ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? Bone Marrow Transplant. 2021;56(4):974–977. doi:https://doi.org/10.1038/s41409-020-01099-4
  • Shibamoto Y, Hayabuchi N, Hiratsuka J-I, et al. Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer. 2003;97(1):128–133. doi:https://doi.org/10.1002/cncr.11035
  • Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021;5(24):5626–5630. doi:https://doi.org/10.1182/bloodadvances.2021005292
  • Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17. doi:https://doi.org/10.1016/0360-3016(92)90538-s

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.